Kenvue Inc. $KVUE Shares Sold by Cresset Asset Management LLC

Cresset Asset Management LLC lessened its stake in Kenvue Inc. (NYSE:KVUE) by 17.3% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 206,053 shares of the company’s stock after selling 43,168 shares during the period. Cresset Asset Management LLC’s holdings in Kenvue were worth $4,313,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Norges Bank purchased a new position in shares of Kenvue in the 2nd quarter valued at approximately $537,418,000. Independent Franchise Partners LLP lifted its holdings in shares of Kenvue by 233.4% during the second quarter. Independent Franchise Partners LLP now owns 31,265,574 shares of the company’s stock worth $654,388,000 after purchasing an additional 21,886,537 shares during the period. Third Point LLC purchased a new position in Kenvue in the 1st quarter valued at $213,422,000. Maverick Capital Ltd. purchased a new position in Kenvue in the 1st quarter valued at $203,036,000. Finally, American Century Companies Inc. increased its stake in Kenvue by 38.6% in the 2nd quarter. American Century Companies Inc. now owns 30,265,020 shares of the company’s stock valued at $633,447,000 after buying an additional 8,436,166 shares during the period. 97.64% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research firms have recently commented on KVUE. Jefferies Financial Group reduced their target price on shares of Kenvue from $25.00 to $23.00 and set a “buy” rating for the company in a research note on Monday, October 27th. Citigroup cut their price target on shares of Kenvue from $20.00 to $17.00 and set a “neutral” rating for the company in a report on Thursday, October 9th. Rothschild Redb raised Kenvue from a “hold” rating to a “strong-buy” rating in a report on Friday, September 26th. Edward Jones cut Kenvue from a “strong-buy” rating to a “hold” rating in a research report on Monday, November 3rd. Finally, Redburn Partners set a $22.00 price target on Kenvue in a report on Friday, September 26th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and thirteen have given a Hold rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $20.23.

Kenvue Price Performance

KVUE stock opened at $16.92 on Monday. The firm has a 50 day moving average of $16.09 and a 200-day moving average of $19.29. The company has a market cap of $32.42 billion, a price-to-earnings ratio of 22.56 and a beta of 0.59. The company has a current ratio of 0.98, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66. Kenvue Inc. has a 12-month low of $14.02 and a 12-month high of $25.17.

Kenvue (NYSE:KVUE) last released its quarterly earnings results on Monday, November 3rd. The company reported $0.28 earnings per share for the quarter, topping analysts’ consensus estimates of $0.27 by $0.01. Kenvue had a return on equity of 20.02% and a net margin of 9.55%.The business had revenue of $3.76 billion for the quarter, compared to analysts’ expectations of $3.83 billion. During the same quarter in the prior year, the firm posted $0.28 EPS. The company’s revenue was down 3.5% compared to the same quarter last year. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. As a group, equities analysts expect that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Wednesday, November 26th. Stockholders of record on Wednesday, November 12th were given a $0.2075 dividend. The ex-dividend date was Wednesday, November 12th. This represents a $0.83 dividend on an annualized basis and a dividend yield of 4.9%. Kenvue’s dividend payout ratio (DPR) is currently 110.67%.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.